【24h】

Assessment of average, population and individual bioequivalence in two- and four-period crossover studies.

机译:在两期和四期交叉研究中评估平均,人群和个体的生物等效性。

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of bioequivalence studies is to assess the equivalence of two pharmaceutical formulations of the same active drug substance. Currently three types of bioequivalence are distinguished: average, population and individual bioequivalence. Average and population bioequivalence can be assessed in two-period (non-replicated) crossover studies, whereas individual bioequivalence requires three- or four-period replicated studies, with a preference for four-period studies. The PC-program BIOEQV80 is presented for the statistical analysis of average and population bioequivalence from two-period crossover studies. The program BIOEQ2X2 is presented for the statistical analysis of all three types of bioequivalence from four-period replicated crossover studies. The statistical aspects of population and individual bioequivalence are based on a recent Guidance issued by the US Food and Drug Administration.
机译:生物等效性研究的目的是评估相同活性药物的两种药物制剂的等效性。当前区分出三种生物等效性:平均值,种群和个体生物等效性。平均和群体生物等效性可以在两期(非重复)交叉研究中进行评估,而单个生物等效性需要三或四期重复研究,而优先选择四期研究。提出了PC程序BIOEQV80,用于对两期交叉研究的平均值和种群生物等效性进行统计分析。提出了程序BIOEQ2X2,用于对来自四个时期的重复交叉研究的所有三种生物等效性进行统计分析。人口和个体生物等效性的统计方面基于美国食品和药物管理局发布的最新指南。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号